Journal of Hypertension · 2019 · 16 citations · 59 references
MedicineEndocrinologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyRenal PathophysiologyDiabetes ManagementDiabetes MellitusGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlObesity ManagementSodium-glucose Cotransporter 2 InhibitorsAntidiabetic Drug TherapyBlood Glucose RegulationCardiovascular Disease ManagementCardiovascular Risk ManagementGlucagon-like Peptide 1 Receptor AgonismSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionType 2 Diabetes Treatment
: The prevalence of type 2 diabetes (T2D) has increased over the past few decades. T2D has a strong genetic propensity that becomes overt when a patient is exposed to a typical Western lifestyle, gain weight and becomes obese, whereas weight loss protects from the development of T2D. Except of lifestyle modifications, the choice of the appropriate treatment is essential in the management of patients with T2D and appears critical for the obese population with T2D. The new pharmacological approach for the treatment of T2D, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, seems to be effective not only in the management of T2D but also for weight loss, reduction of blood pressure and improvement of nonalcoholic fatty liver disease. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 analogues reduced cardiovascular risk, prevented cardiovascular disease and mortality, thereby playing an important role in the treatment of obese patients with hypertension and T2D.
59
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text